» Articles » PMID: 20925068

Gender Differences in Parkinson's Disease: Clinical Characteristics and Cognition

Overview
Journal Mov Disord
Date 2010 Oct 7
PMID 20925068
Citations 157
Authors
Affiliations
Soon will be listed here.
Abstract

More men than women are diagnosed with Parkinson's disease (PD), and a number of gender differences have been documented in this disorder. Examples of clinical characteristics that appear in men more often than women include rigidity and rapid eye movement behavior disorder, whereas more women than men exhibit dyskinesias and depression. Differences between men and women in cognition have not been extensively examined, though there are reports of deficits in men in aspects of cognition that contribute to activities of daily living, in verbal fluency, and in the recognition of facial emotion, and deficits in women in visuospatial cognition. Side of disease onset may interact with gender to affect cognitive abilities. One possible source of male-female differences in the clinical and cognitive characteristics of PD is the effect of estrogen on dopaminergic neurons and pathways in the brain. This effect is not yet understood, as insight into how the fluctuation of estrogen over the lifetime affects the brain is currently limited. Further attention to this area of research will be important for accurate assessment and better management of PD. Attention should also be directed to multiple covariates that may affect clinical characteristics and cognition. Knowledge about differences in the presentation of PD symptoms in men and women and about the pathophysiology underlying those differences may enhance the accuracy and effectiveness of clinical assessment and treatment of the disease.

Citing Articles

A study on the exploration of mild cognitive impairment in Parkinson's disease based on decision-making cognitive computing.

Huang S, Li K, Wang C, Liu J, Li S, Tu Y Front Neurosci. 2025; 18():1495975.

PMID: 39840014 PMC: 11747548. DOI: 10.3389/fnins.2024.1495975.


Gut Microbiota-Based Interventions for Parkinson's Disease: Neuroprotective Mechanisms and Current Perspective.

Kumar D, Bishnoi M, Kondepudi K, Sharma S Probiotics Antimicrob Proteins. 2025; .

PMID: 39809955 DOI: 10.1007/s12602-024-10433-x.


Changes in Subjective Cognitive and Social Functioning in Parkinson's Disease from Before to During the COVID-19 Pandemic.

Mukadam N, Kinger S, Neargarder S, Salazar R, McDowell C, Wall J Healthcare (Basel). 2025; 13(1).

PMID: 39791677 PMC: 11719640. DOI: 10.3390/healthcare13010070.


Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.

Frost E, Shi S, Byroju V, Rissardo J, Donlon J, Vigilante N Brain Sci. 2025; 14(12.

PMID: 39766362 PMC: 11674513. DOI: 10.3390/brainsci14121163.


Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson's disease.

Gu L, Zhang P, Gao R, Shu H, Wang P Front Aging Neurosci. 2024; 16:1465016.

PMID: 39703922 PMC: 11655485. DOI: 10.3389/fnagi.2024.1465016.


References
1.
Munro C, McCaul M, Wong D, Oswald L, Zhou Y, Brasic J . Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. 2006; 59(10):966-74. DOI: 10.1016/j.biopsych.2006.01.008. View

2.
Zappia M, Crescibene L, Arabia G, Nicoletti G, Bagala A, Bastone L . Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol. 2002; 25(2):79-82. DOI: 10.1097/00002826-200203000-00004. View

3.
Van Den Eeden S, Tanner C, Bernstein A, Fross R, Leimpeter A, Bloch D . Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157(11):1015-22. DOI: 10.1093/aje/kwg068. View

4.
Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F . Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol. 2008; 255(2):255-64. DOI: 10.1007/s00415-008-0720-2. View

5.
Clark U, Neargarder S, Cronin-Golomb A . Specific impairments in the recognition of emotional facial expressions in Parkinson's disease. Neuropsychologia. 2008; 46(9):2300-9. PMC: 2491661. DOI: 10.1016/j.neuropsychologia.2008.03.014. View